These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24060176)

  • 1. Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?
    Steggerda MJ; Witteveen T; van den Boom F; Moonen LM
    Radiother Oncol; 2013 Nov; 109(2):251-5. PubMed ID: 24060176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors.
    Steggerda MJ; van der Poel HG; Moonen LM
    Radiother Oncol; 2008 Jul; 88(1):108-14. PubMed ID: 18039548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
    BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S; Cesaretti J; Stone NN; Stock RG
    BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.
    Smith RP; Jones HA; Beriwal S; Gokhale A; Benoit R
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):745-50. PubMed ID: 20888139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.